VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
+35.78%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$276M
AUM Growth
+$276M
(+53%)
Cap. Flow
+$50.8M
Cap. Flow
% of AUM
18.38%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
2
Reduced
1
Closed
–
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$80.6M |
| 2 |
Pharvaris
PHVS
|
$30.1M |
| 3 |
ELEV
Elevation Oncology
ELEV
|
$1.59M |
Top Sells
| 1 |
Ventyx Biosciences
VTYX
|
$61.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SLRN
1
DELISTED
ACELYRIN
SLRN
| $80.6M | 29.18% | +3,857,230 | New | +$80.6M |
|
2
ALX Oncology
ALXO
$62.7M
| $72.8M | 26.36% | 9,699,925 | – | – |
|
|
3
Pharvaris
PHVS
$1.39B
| $64.6M | 23.37% | 4,264,672 +1,986,097 | +87% | +$30.1M |
|
4
Harmony Biosciences
HRMY
$2.12B
| $36.4M | 13.19% | 1,035,396 | – | – |
|
|
5
Ventyx Biosciences
VTYX
$171M
| $13.9M | 5.03% | 424,032 -1,874,801 | -82% | -$61.5M |
|
|
ELEV
6
DELISTED
Elevation Oncology
ELEV
| $4.43M | 1.6% | 2,914,255 +1,047,916 | +56% | +$1.59M |
|
|
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $3.5M | 1.27% | 2,759,791 | – | – |
|